05-01-2021
EfA (Engineering for All), an eHealth Ventures Company, Adds Nobel Laureate Prof. Aaron Ciechanover to its Advisory Board

Tel-Aviv / Yokneam, January 5th, 2020

EfA Technologies is honored and pleased to announce that Prof. Aaron Ciechanover has joined the company’s scientific advisory board.  Prof. Ciechanover, who jointly received the 2004 Nobel prize for chemistry (shared with Drs. A. Hershko and I.A. Rose), is one of the world’s top scientists in the fields of Biology, Chemistry, and Medicine.

His enthusiasm around EfA’s lab-on-hand device is a great achievement to the company and the accreditation of its vision. The company is confident that Prof. Ciechanover will add tremendous expertise, know-how, connections and value to the company’s growth, direction and position in the field of new-age diagnostics and will enhance the deep scientific knowledge around its unique assets and innovative products and technology.


BIO:

Aaron Ciechanover was born in Haifa, Israel in 1947.  He is currently a Distinguished Research Professor in the Faculty of medicine at the Technion – Israel Institute of Technology in Haifa, Israel.  He received his M.Sc. (1971) and M.D. (1973) from the Hebrew University in Jerusalem.  He then completed his national service (1973-1976) as military physician and continued his studies to obtain a doctorate in biological sciences in the Faculty of Medicine in the Technion (D.Sc.; 1982).

There, as a graduate student with Dr. Avram Hershko and in collaboration with Dr. Irwin A. Rose from the Fox Chase Cancer Center in Philadelphia, USA, they discovered that covalent attachment of ubiquitin to a target protein signals it for degradation.  They deciphered the mechanism of conjugation, described the general proteolytic functions of the system, and proposed a model according to which this modification serves as a recognition signal for a specific downstream protease.

As a post-doctoral fellow with Dr. Harvey Lodish at the M.I.T., he continued his studies on the ubiquitin system and made additional important discoveries. Along the years it has become clear that ubiquitin-mediated proteolysis plays major roles in numerous cellular processes, and aberrations in the system underlie the pathogenetic mechanisms of many diseases, among them certain malignancies and neurodegenerative disorders.  Consequently, the system has become an important platform for drug development.

Among the numerous prizes Ciechanover received are the 2000 Albert Lasker Award, the 2002 EMET Prize, the 2003 Israel Prize, and the 2004 Nobel Prize (Chemistry; shared with Drs. Hershko and Rose).  Among many academies, Ciechanover is member of the Israeli National Academy of Sciences and Humanities, The European Molecular Biology Organization (EMBO), the American Academy of Arts and Sciences (Foreign Fellow), the American Philosophical Society, the National Academies of Sciences (NAS) and Medicine (NAM) of the USA (Foreign Associate), the Pontifical Academy of Sciences at the Vatican, the Chinese Academy of Sciences (CAS; Foreign Member), the Russian Academy of Sciences (Foreign Member), and the German Academy of Sciences (Leopoldina).


About EfA

EfA (Engineering for All) Technologies is a team of medical, technology, optical, bioengineering, machine-learning and Finance experts  dedicated to making digital diagnostics truly accessible while delivering the accurate and actionable results necessary for medical diagnoses and treatment in the 21st century.

Contact: amirl@efa-technologies.com

About eHealth Ventures

eHealth Ventures is a multinational consortium of world-class medical organizations, industry leaders, and seasoned financial investors.  Partners include Maccabi – Israel’s leading HMO, the Israeli Innovation Authority (IIA), Amgen – a global biotechnology leader, Medison Pharma – a leading Israeli pharmaceutical company and SCI – a major Chinese VC fund.

eHV is focused on Digital Diagnostics and Home Care, has reviewed over 1200 projects and invested in 14 innovative companies.

Contact: info@ehv.health

EfA Technologies is honored and pleased to announce that Prof. Aaron Ciechanover has joined the company’s scientific advisory board.  Prof. Ciechanover, who jointly received the 2004 Nobel prize for chemistry (shared with Drs. A. Hershko and I.A. Rose), is one of the world’s top scientists in the fields of Biology, Chemistry, and Medicine.

NEWS
We move fast and push our companies to move faster.
Timing is everything - we get it.
For all news items
eHealth Ventures by Numbers:
15
Portfolio Companies
1300
Companies Reviewed
 
 
115
Years of experience for 4 principles
 
7
X
Fair Value Appreciation on Portfolio
Partners & Collaborators